Transaction · 0001742727-26-000002

Naos Yaron

Naos Yaron, SV, COO, reported a transaction classified as grant at Protalix BioTherapeutics, Inc. involving 112000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 112000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ASV, COO
PLXProtalix BioTherapeutics, Inc.
Trade date
Sep 03, 2026
Filing date
Sep 04, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded112k$0.00 per share
Holdings after112kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

PLX price since this filing

Daily closing prices, with the filing date and available return windows
PLX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d -1.1%30d +1.5%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001742727-26-000002
Stock Option (Right to Buy)
Transaction date
Sep 03, 2026
Filed Sep 04, 2026, 10:00 AM · 1d delay
Shares
112,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
112,000 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Sr. VP & COO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

  2. F2

    Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of commo…

  3. F3

    Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

  4. F4

    The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Original filing · 0001742727-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

PLX